尊龙凯时
        








        
	

        















        
    
        
        
        
                            
                                
                        
        
        
        
            
        
                Introduction To Key Projects
            
        
            
        
        
        
        



        
        
        
        
        
    
        

    
        
        
        
            
        OVERVIEW
        
            
        
                
        
                    
        
                        
        
                                                            
        
                                    01
                                    
        R&D Directions
        
                                
        
                            
                                
        
                                    02
                                    
        R&D Projects
        
                                
        
                            
                                
        
                                    03
                                    
        Intellectual Property
        
                                
        
                            
                                
        
                                    04
                                    
        Innovative Platform
        
                                
        
                            
                                
        
                                    05
                                    
        Innovative Talents
        
                                
        
                            
                        
        
                    
        
                
        
                
        
                    
        
                        
        
                            
                                
        
                                    
        
                                        
        
                                            
                                            
        
                                                
        The company aims for the frontier and centers on core product lines. The company stands for innovative drugs, innovative preparations and high-end generic drugs with high clinical value.
                                                    
        
                                        
        
                                    
        
                                    
        
                                        
                                    
        
                                
        
                            

                                
        
                                    
        
                                        
        
                                            
                                            
        
                                                
        More than 500 products under development， projects and more than 60 new drugs of category 1 and 2 under development.
                                                    
        
                                        
        
                                    
        
                                    
        
                                        
                                    
        
                                
        
                            

                                
        
                                    
        
                                        
        
                                            
                                            
        
                                                

        The company has 822 authorized patents, 407 invention patents and 74 overseas authorized patents.
        

        The scope of patents covers many countries and regions including Europe, USA, Japan, Russia, Australia, New Zealand, Mexico, Hong Kong, China, and Taiwan, China.
        
                                            
        
                                        
        
                                    
        
                                    
        
                                        
                                    
        
                                
        
                            

                                
        
                                    
        
                                        
        
                                            
                                            
        
                                                

        The company continues to build and improve the high-end technology platform, and promotes technology transfer and import of new products through industry-university-research cooperation.
        

        While building a first-class platform for R&D and innovation, the company provides all-around service from research, development, and clinical trials to registration of new drugs.
        
                                            
        
                                        
        
                                    
        
                                    
        
                                        
                                    
        
                                
        
                            

                                
        
                                    
        
                                        
        
                                            
                                            
        
                                                

        The company has a scientific research team with overseas pharmaceutical experts, domestic pharmaceutical doctors, and masters as core personnel.
        

        Today, the company has more than 2,000 research and development personnel, including more than 120 doctors, and 7 experts enjoying a special allowance of The State Council.
        
                                            
        
                                        
        
                                    
        
                                    
        
                                        
                                    
        
                                
        
                            
                        
        
                        
        
                        
        
                    
        

                
        

            
        
            
        

                
        
                    
        
                        
        
                            
                                
        
                                    
        
                                        
                                    
        
                                    
        
                                        
                                        
        
                                            The company aims for the frontier and centers on core product lines. The company stands for innovative drugs, innovative preparations and high-end generic drugs with high clinical value.                                        
        
                                    
        
                                
        
                            

                                
        
                                    
        
                                        
                                    
        
                                    
        
                                        
                                        
        
                                            More than 500 products under development， projects and more than 60 new drugs of category 1 and 2 under development.                                        
        
                                    
        
                                
        
                            

                                
        
                                    
        
                                        
                                    
        
                                    
        
                                        
                                        
        
                                            The company has 822 authorized patents, 407 invention patents and 74 overseas authorized patents.The scope of patents covers many countries and regions including Europe, USA, Japan, Russia, Australia, New Zealand, Mexico, Hong Kong, China, and Taiwan, Chi                                        
        
                                    
        
                                
        
                            

                                
        
                                    
        
                                        
                                    
        
                                    
        
                                        
                                        
        
                                            The company continues to build and improve the high-end technology platform, and promotes technology transfer and import of new products through industry-university-research cooperation.While building a first-class platform for R&D and innovation, the                                        
        
                                    
        
                                
        
                            

                                
        
                                    
        
                                        
                                    
        
                                    
        
                                        
                                        
        
                                            The company has a scientific research team with overseas pharmaceutical experts, domestic pharmaceutical doctors, and masters as core personnel.Today, the company has more than 2,000 research and development personnel, including more than 120 doctors, and                                        
        
                                    
        
                                
        
                            
                        
        
                        
        
                    
        



                
        

            
        
        
        
    
        

    
        
        
        
            
        
                
        
                    
        
                        
                            
                        
                    
        
                    
        
                        
        Development Progress
        
                        
                    
        
                
        
                
        
                    
        
                        
                            
                        
                    
        
                    
        
                        
        R&D Centers
        
                        
                    
        
                
        
            
        
        
        
    
        

    
        
        
        
            
        Technology Platform
        
            
        
                
                    
        
                        
        
                            
                        
        
                        
        Technology platform for innovative small molecule drugs
        
                        
        Design of novel molecules that are non-addictive and non-respiratory depressant.
        
                    
        
                

                    
        
                        
        
                            
                        
        
                        
        Technology platform for long-acting microspheres and liposomes
        
                        
        Sustained-release microsphere injections which can provide analgesia and local anesthesia for more than 24 hours after single injection.
        
                    
        
                

                    
        
                        
        
                            
                        
        
                        
        Technology platform for transdermal administration
        
                        
        Sufentanil transdermal patch and other products have no first-pass effect and high bioavailability.
        
                    
        
                

                    
        
                        
        
                            
                        
        
                        
        Technology platform for anti-abuse design of special drugs
        
                        
        Drugs including Hydrocodone Sustained-release Tablets and Oxycodone Sustained-release Tablets, are designed to be difficult to crush, difficult to extract and difficult to be abused.
        
                    
        
                

                    
        
                        
        
                            
                        
        
                        
        Technology platform for oral sustained-release and controlled -release drugs
        
                        
        To make the blood concentration stable and the side effects reduced for hydromorphone sustained-release tablets.
        
                    
        
                

                    
        
                        
        
                            
                        
        
                        
        Technology platform for oral mucous administration
        
                        
        Fententanil oral patches and other products are absorbed through mucous membranes and can take effect quickly.
        
                    
        
                
            
        
        
        
    
        
    
        
        
        
            
        Technology Platform
        
            
        
                
        
                    
                        
        
                            
        
                                
                            
        
                            
        
                                
        Technology platform for innovative small molecule drugs
        
                                
        Design of novel molecules that are non-addictive and non-respiratory depressant.
        
                            
        
                        
        
                    

                        
        
                            
        
                                
                            
        
                            
        
                                
        Technology platform for long-acting microspheres and liposomes
        
                                
        Sustained-release microsphere injections which can provide analgesia and local anesthesia for more than 24 hours after single injection.
        
                            
        
                        
        
                    

                        
        
                            
        
                                
                            
        
                            
        
                                
        Technology platform for transdermal administration
        
                                
        Sufentanil transdermal patch and other products have no first-pass effect and high bioavailability.
        
                            
        
                        
        
                    

                        
        
                            
        
                                
                            
        
                            
        
                                
        Technology platform for anti-abuse design of special drugs
        
                                
        Drugs including Hydrocodone Sustained-release Tablets and Oxycodone Sustained-release Tablets, are designed to be difficult to crush, difficult to extract and difficult to be abused.
        
                            
        
                        
        
                    

                        
        
                            
        
                                
                            
        
                            
        
                                
        Technology platform for oral sustained-release and controlled -release drugs
        
                                
        To make the blood concentration stable and the side effects reduced for hydromorphone sustained-release tablets.
        
                            
        
                        
        
                    

                        
        
                            
        
                                
                            
        
                            
        
                                
        Technology platform for oral mucous administration
        
                                
        Fententanil oral patches and other products are absorbed through mucous membranes and can take effect quickly.
        
                            
        
                        
        
                    
                
        
                
        
            
        
        
        
    
        

    
        
        
        
            
        Introduction of key projects
        
            
        
                
        
                                                    
        
                                
                                
        
                                    
        
                                        
        Remazolam Besylate for Injection-Category 1 new drug
        
                                    
        
                                    
        
                                        
        Remazolam Besylate for Injection (Brand name: RuiMa®) obtained the Drug Registration Certificate issued by National Medical Products Administration in July 2020.
        
                                        
        Remazolam Besylate belongs to benzodiazepines and is a novel ultra-short-acting GABAA receptor agonist. It is metabolized by tissue esterase and the metabolites are inactive. Compared with similar products, it has the following clinical advantages: rapid onset of action, patient can wake quickly, lower respiratory/circulatory inhibition, there are specific antagonists, etc. In the future, it has wide applications in fields including painless diagnosis, treatment and sedation, general anesthesia, sedation in ICU, local anesthesia, and sedation.
        
                                    
        
                                
        
                            
        
                        
                            
        
                                
                                
        
                                    
        
                                        
        Fospropofol Disodium for Injection-Category 1 new drug
        
                                    
        
                                    
        
                                        
        Fospropofol Disodium for Injection (Brand name: LinBingFen®) obtained the Drug Registration Certificate issued by National Medical Products Administration in May 2021.
        
                                        
        Fospropofol Disodium for Injection, is a new type of short-acting intravenously administered general anesthetic, and is also one of the most advanced intravenously administered general anesthetics studied at home and abroad. It is metabolized into the active substance propofol in the body to produce anesthetic effect and does not need the fat emulsion as vehicle of propofol preparations; during clinical application, it can reduce the pain of intravenous injection, and avoid the possible dyslipidemia caused by fat emulsion vehicle, bringing better surgical options for doctors and providing patients with a more comfortable experience of medical treatment.
        
                                    
        
                                
        
                            
        
                        
                            
        
                                
                                
        
                                    
        
                                        
        Snowbellleaf Tickclover General Flavone Capsule-Category 1 new drug
        
                                    
        
                                    
        
                                        
        Snowbellleaf Tickclover General Flavone Capsule (Brand name: Guang Shi Tong®) obtained the Drug Registration Certificate issued by National Medical Products Administration in September 2022.
        
                                        
        Snowbellleaf Tickclover General Flavone Capsule, is a new Category 1.2 drug with independent intellectual property rights, which is obtained by extracting and purifying the effective parts of general flavone from the Snowbellleaf Tickclover using modern medical technology. Its major functions are to clear heat, expel damp, diuresis, and expel stone. It is used to treat ureteral calculi with accumulation of dampness and heat due to TCM differentiation. The product has the functions of diuresis, promoting stone discharge, anti-inflammatory effect, analgesia, etc. Compared with similar varieties, it can significantly improve the efficiency of stone removal in patients with ureteral calculi, especially for patients with large calculi who respond poorly to current medication treatment. It can reduce unnecessary surgical treatment, relieve patients' pain, reduce medical burden. Thus, it has a good value in clinical application.
        
                                    
        
                                
        
                            
        
                        
                    
        
                
        
            
        
        
        
    
        


    
        
        
        
            
        Introduction of key projects
        
            
        
                                    
        
                        
                        
        

                            
        
                                
        Remazolam Besylate for Injection (Brand name: RuiMa®) obtained the Drug Registration Certificate issued by National Medical Products Administration in July 2020.
        
                                
        Remazolam Besylate belongs to benzodiazepines and is a novel ultra-short-acting GABAA receptor agonist. It is metabolized by tissue esterase and the metabolites are inactive. Compared with similar products, it has the following clinical advantages: rapid onset of action, patient can wake quickly, lower respiratory/circulatory inhibition, there are specific antagonists, etc. In the future, it has wide applications in fields including painless diagnosis, treatment and sedation, general anesthesia, sedation in ICU, local anesthesia, and sedation.                                
        
                            
        
                        
        
                    
        
                
                    
        
                        
                        
        

                            
        
                                
        Fospropofol Disodium for Injection (Brand name: LinBingFen®) obtained the Drug Registration Certificate issued by National Medical Products Administration in May 2021.
        
                                
        Fospropofol Disodium for Injection, is a new type of short-acting intravenously administered general anesthetic, and is also one of the most advanced intravenously administered general anesthetics studied at home and abroad. It is metabolized into the active substance propofol in the body to produce anesthetic effect and does not need the fat emulsion as vehicle of propofol preparations; during clinical application, it can reduce the pain of intravenous injection, and avoid the possible dyslipidemia caused by fat emulsion vehicle, bringing better surgical options for doctors and providing patients with a more comfortable experience of medical treatment.                                
        
                            
        
                        
        
                    
        
                
                    
        
                        
                        
        

                            
        
                                
        Snowbellleaf Tickclover General Flavone Capsule (Brand name: Guang Shi Tong®) obtained the Drug Registration Certificate issued by National Medical Products Administration in September 2022.
        
                                
        Snowbellleaf Tickclover General Flavone Capsule, is a new Category 1.2 drug with independent intellectual property rights, which is obtained by extracting and purifying the effective parts of general flavone from the Snowbellleaf Tickclover using modern medical technology. Its major functions are to clear heat, expel damp, diuresis, and expel stone. It is used to treat ureteral calculi with accumulation of dampness and heat due to TCM differentiation. The product has the functions of diuresis, promoting stone discharge, anti-inflammatory effect, analgesia, etc. Compared with similar varieties, it can significantly improve the efficiency of stone removal in patients with ureteral calculi, especially for patients with large calculi who respond poorly to current medication treatment. It can reduce unnecessary surgical treatment, relieve patients' pain, reduce medical burden. Thus, it has a good value in clinical application.